&nbsp;

Sep 2024

Drug

riTUXimab

Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™

Quick Link(s):

Jun 2025

Drug

nab-PACLitaxel

Other Name(s): Abraxane®

Quick Link(s):

Dec 2024

Drug

ruxolitinib

Other Name(s): Jakavi®

Quick Link(s):

Mar 2025

Drug

regorafenib

Other Name(s): Stivarga®

Quick Link(s):

Nov 2023

Drug

romidepsin

Other Name(s): Istodax®

Quick Link(s):

Mar 2023

Drug

nelarabine

Other Name(s): Atriance®

Quick Link(s):

Apr 2024

Drug

ramucirumab

Other Name(s): Cyramza®

Quick Link(s):

Jan 2026

Regimen

NPAC

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

Drugs Used:

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma

Drugs Used:

riTUXimab

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

RITU(MNT)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma

Drugs Used:

riTUXimab

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

NILO

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

niLOtinib - Chronic phase Ph+ CML, with specific criteria

Exceptional Access Program

niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria

Drugs Used:

niLOtinib